(AOF) – Chemours announces the appointment of Denise Dignam as president and CEO of the group. This American chemist specializing in titanium technologies, thermal solutions and advanced performance materials specifies that Denise Dignam, interim general manager since February 2024, and who joined him in 2015 after more than 7 years at DuPont, brings more than 35 years of experience in the chemical industry. She has held leadership positions in sales and marketing, merchandising and supply chain.
As President of Chemours’ Titanium Technologies division, Denise Dignam implemented a transformation plan, achieved significant operational savings, refocused the portfolio to deliver greater customer value and developed process improvements for better use of resources throughout the manufacturing cycle.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.